Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-ß1.

AIMS: Animal studies show that transforming growth factor-ß1 (TGF-ß1) is an important mediator of atrial fibrosis and atrial fibrillation (AF). This study investigated the role of TGF-ß1 in human AF and the mechanism of atrial-selective fibrosis. METHODS AND RESULTS: Atrial specimens from 17 open heart surgery patients and left atrial and ventricular specimens from 17 explanted hearts were collected to assess the relationship between TGF-ß1, AF, and differential atrial vs. ventricular TGF-ß1 levels. A transgenic mouse model overexpressing active TGF-ß1 was used to study the mechanisms underlying the resultant atrial-selective fibrosis. Higher right atrial total TGF-ß1 levels (2.58 ± 0.16-fold, P < 0.0001) and active TGF-ß1 (3.7 ± 0.7-fold, P = 0.013) were observed in those that developed post-operative AF. Although no ventricular differences were observed, 11 explanted heart failure hearts exhibited higher atrial TGF-ß1 levels than 6 non-failing hearts (2.30 ± 0.87 fold higher, P < 0.001). In the transgenic mouse, TGF-ß1 receptor-1 kinase blockade resulted in decreased atrial expression of fibrosis-related genes. By RNA microarray analyses in that model, 80 genes in the atria and only 2 genes in the ventricle were differentially expressed. Although these mice atria, but not the ventricles, exhibited increased expression of fibrosis-related genes and phosphorylation of Smad2, there were no differences in TGF-ß1 receptor levels or Smads in the atria compared with the ventricles. CONCLUSIONS: TGF-ß1 mediates selective atrial fibrosis in AF that occurs via TGF-ß Receptor 1/2 and the classical Smad pathway. The differential atrial vs. ventricular fibrotic response occurs at the level of TGF-ß1 receptor binding or phosphorylation.